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Summary
Background The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal 
radiotherapy in patients with localised prostate cancer. Preliminary ﬁ ndings reported after 5 years of follow-up showed 
that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample 
size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, 
after a median 10 years of follow-up.
Methods RT01 was a phase 3, open-label, international, randomised controlled trial enrolling men with histologically 
conﬁ rmed T1b–T3a, N0, M0 prostate cancer with prostate speciﬁ c antigen of less than 50 ng/mL. Patients were randomly 
assigned centrally in a 1:1 ratio, using a computer-based minimisation algorithm stratifying by risk of seminal vesicle 
invasion and centre to either the control group (64 Gy in 32 fractions, the standard dose at the time the trial was designed) 
or the escalated-dose group (74 Gy in 37 fractions). Neither patients nor investigators were masked to assignment. All 
patients received neoadjuvant androgen deprivation therapy for 3–6 months before the start of conformal radiotherapy, 
which continued until the end of conformal radiotherapy. The coprimary outcome measures were biochemical 
progression-free survival and overall survival. All analyses were done on an intention-to-treat basis. Treatment-related 
side-eﬀ ects have been reported previously. This trial is registered, number ISRCTN47772397.
Findings Between Jan 7, 1998, and Dec 20, 2001, 862 men were registered and 843 subsequently randomly assigned: 
422 to the escalated-dose group and 421 to the control group. As of Aug 2, 2011, 236 deaths had occurred: 118 in each 
group. Median follow-up was 10·0 years (IQR 9·1–10·8). Overall survival at 10 years was 71% (95% CI 66–75) in each 
group (hazard ratio [HR] 0·99, 95% CI 0·77–1·28; p=0·96). Biochemical progression or progressive disease occurred 
in 391 patients (221 [57%] in the control group and 170 [43%] in the escalated-dose group). At 10 years, biochemical 
progression-free survival was 43% (95% CI 38–48) in the control group and 55% (50–61) in the escalated-dose group 
(HR 0·69, 95% CI 0·56–0·84; p=0·0003).
Interpretation At a median follow-up of 10 years, escalated-dose conformal radiotherapy with neoadjuvant androgen 
deprivation therapy showed an advantage in biochemical progression-free survival, but this advantage did not 
translate into an improvement in overall survival. These eﬃ  cacy data for escalated-dose treatment must be weighed 
against the increase in acute and late toxicities associated with the escalated dose and emphasise the importance of 
use of appropriate modern radiotherapy methods to reduce side-eﬀ ects.
Funding UK Medical Research Council.
Copyright © Dearnaley et al. Open Access article distributed under the terms of CC BY.
Introduction
External beam radiotherapy is one of the standard curative 
options for men with localised prostate cancer and is 
particularly appropriate for men with intermediate-risk or 
high-risk disease.1,2 Improved radiotherapy techniques, 
such as conformal radiotherapy, allow high treatment 
doses to be given safely3,4 and several phase 3 randomised 
controlled trials of dose escalation have reported improved 
biochemical progression-free survival.5–10 The Medical 
Research Council (MRC) RT01 trial is the largest of these 
trials to have reported results, and since its initial report of 
results dose-escalated conformal radiotherapy has been 
the standard of care in the UK since 2008.1 The trial 
mandated the use of short-course neoadjuvant androgen 
deprivation therapy (ADT); neoadjuvant ADT has since 
been shown to improve overall and cancer-speciﬁ c survival 
in patients with advanced localised disease.11–14
The aim of the RT01 trial was to assess the eﬀ ect of 
dose-escalation on overall survival, biochemical 
progression-free survival, and toxicity, by comparing 
doses of 74 Gy and 64 Gy delivered by use of conformal 
radiotherapy techniques. 64 Gy in  32 fractions was 
chosen as the radiotherapy schedule for the control group 
in our randomised trial, because that was the standard 
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dose at the time the trial was designed. We initially 
reported ﬁ ndings of the trial with a 5-year median follow-
up and now update these results with a median follow-up 
of 10 years, because the target number of deaths for 
analysis of overall survival has been reached. Treatment-
related side-eﬀ ects have been reported previously.7,15,16
Methods
 Study design and participants
RT01 was a phase 3, open-label, international, 
randomised controlled trial comparing dose-escalated 
conformal radiotherapy with control-dose conformal 
radiotherapy. It was preceded by a pilot study at the Royal 
Marsden Hospital.5 Patients were registered, initiated on 
neoadjuvant ADT, and then randomly assigned to receive 
either control or escalated radiotherapy using conformal 
radiotherapy techniques. Men 18 years or older with 
histologically conﬁ rmed T1b–T3a, N0, M0 prostate 
cancer and prostate-speciﬁ c antigen (PSA) of less than 
50 ng per mL, with no contraindications for radical 
radiotherapy were included in the trial. All patients gave 
written informed consent. The trial was overseen by a 
trial management group and reviewed on three occasions 
by an independent data-monitoring committee. No 
formal stopping rules were speciﬁ ed. At each review, the 
Data Monitoring and Ethics Committee re com mended 
that the trial could continue. This study was done in 
compliance with the Declaration of Helsinki, and the 
protocol was approved by the appropriate Research 
Ethics Committees.
Randomisation and masking
Consenting patients were randomly assigned in a 1:1 ratio 
to control or escalated-dose conformal radiotherapy 
centrally at the MRC clinical trials unit (CTU) using a 
computer-based minimisation algorithm, stratifying for 
risk of seminal vesicle invasion and centre. Sites phoned 
MRC CTU to randomise patients. Neither participants 
nor investigators were masked to the allocated treatment 
because blinding was not practicable. The random 
allocation list was created by the MRC CTU.
Procedures
As reported previously, androgen deprivation was 
achieved using injections of luteinising-hormone-
releasing hormone agonists every 4 weeks and was 
accompanied by antiandrogen therapy to prevent ﬂ are 
events.7 Neoadjuvant ADT was given for 3–6 months 
before commencement of conformal radiotherapy and 
continued until the end of conformal radiotherapy.
Men were randomised to receive either a control-dose 
schedule (64 Gy in 32 fractions; control group) schedule, or 
an escalated-dose schedule (74 Gy in 37 fractions). All 
radiotherapy treatments used three-dimensional con-
formal techniques as previously described.7,11,17 The 
radiotherapy phase 1 target volume included the prostate 
and all or part of the seminal vesicles, depending on the 
Figure 1: Trial proﬁ le
421 patients assigned to control group 
         (64 Gy in 32 fractions)
 4 received more than planned dose
 410 received planned dose
 2 had less than planned dose
 4 did not receive radiotherapy 
 1 dose information not available
422 patients assigned to escalated-dose group 
         (74 Gy in 37 fractions)
 401 received planned dose
 14 received less than planned dose
 7 did not receive radiotherapy 
421 patients analysed 422 patients analysed
862 assessed for eligibility
19 excluded 
 8 intercurrent illness
 6 patient’s preference 
 3 hospital error 
 2 disease progression 
843 randomised
Control group 
(N=421)
Escalated-dose 
group (N=422)
Age (years)
Median (range) 67 (46–80) 67 (48–80)
T stage
T1b/T1c 106 (26%) 103 (25%)
T2a/T2b 236 (57%) 239 (57%)
T3a/T3b 71 (17%) 76 (18%)
Not known 8 4
Gleason score*
6 or lower 261 (62%) 249 (59%)
7 105 (25%) 117 (28%)
8 or higher 52 (12%) 54 (13%)
Not known 3 2
Prehormone PSA (ng/mL)
Median (IQR) 12·8 (8·4–20·0) 12·8 (7·8–20·2)
Mean (SD) 15·6 (10·0) 15·2 (9·6)
Risk group for involvement of seminal vesicles
Low 137 (33%) 138 (33%)
Moderate 284 (67%) 284 (67%)
NCCN risk group*
Low 79 (19%) 81 (19%)
Intermediate 159 (38%) 152 (36%) 
High 178 (43%) 184 (44%)
Unobtainable 5 5
Data are n (%) unless otherwise speciﬁ ed. Percentages exclude missing data. 
Some percentages do not total 100% because of rounding. PSA=prostate-speciﬁ c 
antigen. NCCN=National Comprehensive Cancer Network. *If Gleason score was 
missing, WHO diﬀ erentiation was used in the following way: well, moderate, or 
poor diﬀ erentiation is classiﬁ ed as Gleason score of 6, 7, or 8, respectively. 
Table 1: Baseline characteristics
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risk of seminal vesicle invasion.18 All patients were treated 
to a dose of 64 Gy in 32 fractions over 6·5 weeks using a 
standard three-ﬁ eld plan (anterior ﬁ eld and left and right 
lateral or posterior oblique ﬁ elds) with a 1·0 cm margin. 
Patients randomised to the escalated-dose group had a 
phase 2 boost to the prostate alone using a six-ﬁ eld 
technique (left and right anterior oblique, left and right 
posterior oblique, and left and right lateral ﬁ elds) with no 
margin added. The boost radiotherapy followed the phase 
1 treatment. All doses were prescribed to the isocentre. 
Beam shaping was with multileaf collimators or 
customised shaped blocks and treatment was delivered 
with 6–10 MV photons. No dose constraints for normal 
tissues were speciﬁ ed. Veriﬁ cation was with daily and then 
weekly port ﬁ lms and images.
Men were followed-up throughout radiotherapy at 
6 monthly intervals up to 2 years, and annually thereafter. 
Acute and late treatment-related side-eﬀ ects were collected 
using Radiation Therapy Oncology Group19 and Late Eﬀ ects 
of Normal Tissues-Subjective Objective Management 
Analytic scales20 and timed from the start of radiotherapy. 
Disease assessments were PSA, digital rectal examination, 
and symptoms. Technetium-99m bone scans, CT, or MRI 
were done as clinically indicated. The design, objectives, 
eligibility criteria for patients, treatment methods, and 
statistical considerations are detailed elsewhere.7,17
Outcomes
The coprimary outcome measures were overall survival 
and biochemical progression-free survival. Overall 
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Figure 2: Primary analysis of overall survival and biochemical progression-free survival
(A) Overall survival, predicted from Kaplan-Meier function and ﬂ exible parametric model. (B) Absolute diﬀ erence in overall survival, from ﬂ exible parametric model. (C) Biochemical progression-free 
survival, predicted by Kaplan-Meier function and ﬂ exible parametric model. (D) Absolute diﬀ erence in biochemical progression-free survival, from ﬂ exible parametric model.
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survival was deﬁ ned as time from randomisation to 
death from any cause or censoring at date of last contact. 
Biochemical progression-free survival was deﬁ ned as 
time from randomisation to biochemical failure, death 
from prostate cancer, or development of local, nodal, or 
metastatic disease, whichever occurred ﬁ rst.
Additional outcome measures were biochemical failure 
(an increase in PSA concentration to 50% above nadir 
and above 2 ng/mL 6 months or more after the start of 
radiotherapy); progression-free survival (excluding PSA 
failure); initiation of long-term salvage ADT; development 
of metastases; death from prostate cancer; and metastases-
free survival (time to development of any metastases or 
death from prostate cancer). Cause of death was reviewed 
by pairs of clinicians from a panel of ﬁ ve individuals who 
were masked to treatment allocation.
The original protocol speciﬁ ed ﬁ ve primary outcome 
measures (biochemical progression-free survival 
[named as “biochemical control” in the protocol, 
freedom from local progression, metastases free 
survival, overall survival, and late toxicity); with sample 
size calculations included for local control and overall 
survival. During the course of the trial, the Trial 
Management Group, Independent Data Monitoring 
Committee, and Trial Steering Committee agreed from 
external evidence that biochemical progression-free 
survival was a more important outcome measure than 
local control. Therefore, the trigger for intermediate 
and long-term analyses has been biochemical 
progression-free survival and overall survival. All 
outcome measures are reported.
Statistical analysis
We estimated that inclusion of about 800 patients would 
meet the targets for the numbers of patients in the 
subgroups at low-risk and intermediate-risk of seminal 
vesicle involvement.17 We assumed that survival at 5 years 
would be 50% in patients in the control group, and the 
trial aimed to achieve a 15% increase in survival at 5 years 
in the escalated-dose group. Assuming proportional 
hazards, this improvement corresponds to a hazard ratio 
(HR) of 0·62. With 90% power and a 5% two-sided 
signiﬁ cance level, we established that about 194 deaths 
were needed for this analysis of overall survival.
We did all analyses on an intention-to-treat basis, with 
patients analysed according to allocated treatment group. 
We used a two-sided 5% signiﬁ cance level for all analyses. 
All analysed outcome measures are presented in this 
report.
We used standard survival analysis methods to 
investigate time from randomisation to the ﬁ rst reported 
event for each outcome measure, except for time to death 
from prostate cancer. Patients who have not yet reported 
the relevant event are censored at the date of last contact. 
Median follow-up time was established with the reverse 
Kaplan-Meier method. The assumption of proportionality 
of hazards was tested. Hazard ratios (HR) were estimated 
with Cox models, adjusted for seminal vesicle risk 
group.18 We applied the restricted mean survival time 
method to overall survival and biochemical progression-
free survival, as an additional method of estimating 
diﬀ erence between the treatments, with the restriction 
time being 10 years. We used ﬂ exible parametric 
modelling to estimate restricted mean survival time. 
All comparisons are expressed relative to the control 
group; therefore, an HR of less than 1·0 indicates a 
decreased risk in the escalated-dose group.
We did a competing-risk analysis for prostate cancer 
death because the number of deaths from causes other 
than prostate cancer exceeded the prespeciﬁ ed level of 
20%. For this analysis, time to prostate cancer death is 
presented with cumulative incidence function rather 
than survival function; sub-HR is presented with 95% CI 
and p value. We used the method of Fine and Gray21 to 
estimate sub-HR. Cause-speciﬁ c HRs are presented for 
both prostate cancer and non-prostate-cancer deaths.
We did pre-planned, exploratory subgroup analyses to 
examine consistency of eﬀ ect across seminal vesicle risk 
group (low vs moderate) and National Comprehensive 
Cancer Network (NCCN) risk group (low vs intermediate 
vs high).2 This analysis uses χ² tests for heterogeneity of 
interaction or trend when appropriate, and examines 
overall survival and biochemical progression-free 
survival. A health economic analysis is planned.
We used Stata (version 12.1) for analyses. This trial is 
registered, number ISRCTN47772397.
Figure 3: Subgroup analyses of overall survival and biochemical progression-free survival
(A) Overall survival and risk of seminal vesicle involvement. (B) Overall survival and National Comprehensive Cancer 
Network risk group. (C) Biochemical progression-free survival and risk of seminal vesicle involvement. 
(D) Biochemical progression-free survival and National Comprehensive Cancer Network risk group. HR=hazard ratio.
A
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Intermediate risk
Test for heterogeneity: p=0·89
B
Low risk
Intermediate risk
High risk
Test for heterogeneity: p=0·70
C
Low-risk
Intermediate-risk
Test for heterogeneity: p=0·42
D
Low risk
Intermediate risk
High risk
Test for heterogeneity: p=0·32
0·96 (0·54–1·70)
1·01 (0·76–1·34)
0·77 (0·32–1·87)
1·13 (0·73–1·74)
0·95 (0·68–1·34)
0·80 (0·54–1·18)
0·66 (0·52–0·83)
0·61 (0·34–1·09)
0·84 (0·59–1·19)
0·60 (0·46–0·79)
HR (95% CI)
Favours escalated-dose Favours control
1·00·5 2·0
Articles
468 www.thelancet.com/oncology   Vol 15   April 2014
Role of the funding source
The trial was sponsored by UK Medical Research Council 
and conducted by the MRC Clinical Trials Unit (from 
August, 2013, part of University College London). MRC 
employees were central to the conduct of the trial and the 
development of this report. The sponsor of the trial had 
no role in trial design, data analysis, or data interpretation. 
MRS and GJ had access to raw data. MRS had access to 
all data in the trial and had ﬁ nal responsibility for the 
decision to submit for publication. 
Results
Between Jan 7, 1998, and Dec 20, 2001, 862 men were 
registered and 843 subsequently randomised: 422 to the 
escalated-dose group and 421 to the control group (ﬁ gure 1).
Table 1 shows characteristics of the patients at baseline; 
the groups were balanced. Overall, median age was 
67 years (IQR 63–71), and presenting median PSA was 
12·8 (IQR 8·1–20·0). 209 (25%) of 831 patients had 
T1 stage cancers, 475 (57%) had T2 stage, and 147 (18%) 
had T3 cancers; T stage was unavailable for 12 patients. 
Analyses of biopsy specimens were reported by local 
histopathologists, and showed Gleason scores of 6 or 
lower in 510 (61%) of the 838 enrolled patients, a score 
of 7 in 222 (26%) of patients, and a score 8 of or higher in 
13% (106) of patients; Gleason score was not available for 
ﬁ ve patients. 160 (19%) of 833 patients had low-risk 
disease according to NCCN criteria, 311 (37%) had 
intermediate-risk disease, and 362 (43%) had high-risk 
disease; unavailability of T-stage or histological grading 
precluded ascertainment of risk group in ten patients. 
275 (33%) of 843 patients had a low risk of seminal vesicle 
involvement; 568 (67%) had intermediate or high risk. 
Median follow-up was 10·0 years (IQR 9·1–10·8; range 
0·6–13·4). Overall, 117 patients were alive at 11 years and 
30 at 12 years.
As of Aug 2, 2011, 236 deaths had been reported, 118 in 
each group, triggering the overall survival analysis. There 
was no diﬀ erence in 10 year overall survival between 
groups: 10 year overall survival was 71% (95% CI 66–75) in 
both groups (HR 0·99, 95% CI 0·77–1·28, p=0·96, 
ﬁ gure 2). Mean overall survival, using the ﬂ exible 
parametric model and when restricted to 10 years, was 
9·30 years (95% CI 9·08–9·52) for the control group and 
9·28 years (9·06–9·50) for the escalated-dose group. There 
was no evidence of a diﬀ erence between restricted mean 
survival: –0·02 years (95% CI –0·34 to 0·29; p=0·88).
For patients who had not yet reported a biochemical 
progression event, adherence to PSA testing was 90% 
complete at 5 years and 76% complete at 10 years. 
Adherence patterns were much the same in the two 
randomised groups (appendix). 391 biochemical 
progression events occurred: 221 (57%) in the control 
group and 170 (43%) in the escalated-dose group. 
Biochemical progression-free survival was better in the 
escalated-dose group, being 43% at 10 years 
(95% CI 38–48) in the control group and 55% (50–61) in 
the escalated-dose group (HR 0·69, 95% CI 0·56–0·84; 
p=0·0003, ﬁ gure 2). Mean biochemical progression-
free survival, when time of analysis was restricted to 
10 years, was 7·33 years (95% CI 6·87–7·80) in the 
control group and 8·01 years (7·60–8·40) in the 
escalated-dose group, leading to an improvement in 
restricted mean survival of 0·69 years with escalated-
dose radiotherapy (95% CI 0·08–1·30; p=0·03). This 
ﬁ nding represents a relative improvement of about 10% 
in the escalated-dose group compared to the control 
group.
See Online for appendix
HR (Escalated 
vs Control)
95% CI p value Control group 
events
Escalated-dose 
group events
Control group at 
10 years 
(% [95% CI])
Escalated-dose 
group 10 years 
(% [95% CI])
Primary
Overall survival 0·99 0·77–1·28 0·96 118 118 71% (66–75) 71% (66–75)
Biochemical progression-free survival* 0·69 0·56–0·84 0·0003 221 170 43% (38–48) 55% (50–61)
Additional
Biochemical failure† 0·67 0·55–0·83 0·0003 208 157 45% (40–51) 58% (53–64)
Initiation of ADT 0·76 0·58–0·99 0·04 123 97 68% (63–73) 74% (69–79)
PFS‡ 0·76 0·60–0·97 0·03 148 120 61% (56–66) 69% (64–74)
Any metastases 0·94 0·62–1·42 0·76 46 44 88% (84–91) 88% (84–91)
MFS§ 0·94 0·67–1·32 0·72 67 65 82% (77–86) 83% (78–87)
Time to prostate cancer death 1·07¶ 0·71–1·61 0·75 ·· ·· ·· ··
Prostate cancer death 1·06|| 0·70–1·60 0·79 44 47 11% (9–14) 11% (9–13)
Non-prostate cancer death 0·96|| 0·69–1·32 0·78 74 71 18% (15–21) 18% (15–21)
The assumption of proportional hazards was tested and there was no evidence of non-proportionality for any of the outcome measures; therefore, HR is an appropriate 
summary measure. HR=hazard ratio. ADT=androgen deprivation therapy. PFS=progression-free survival. MFS=metastases-free survival. *Deﬁ ned as PSA failure or PFS event. 
†Deﬁ ned as PSA greater than 2 ng/mL, 6 months or more after commencement of radiotherapy and PSA rising from nadir concentration by 50% or more. ‡Deﬁ ned as local 
progression, lymph node, bone or other metastases, prostate-cancer-related death, or restart of ADT. §Deﬁ ned as bone or other metastases or prostate-cancer-related death. 
¶Sub-HR. ||Cause-speciﬁ c HR.
Table 2: Outcome measures
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Figure 3 shows subgroup analyses by seminal vesicle 
involvement and NCCN risk group. We identiﬁ ed no 
diﬀ erence in the treatment eﬀ ect across these subgroups 
in overall survival and biochemical progression-free 
survival. Progression-free survival, biochemical failure, 
and delayed commencement of salvage ADT were all 
signiﬁ cantly better in the escalated-dose group 
compared to the control group (table 2, ﬁ gure 4). Of 
patients who had biochemical progression, a lower 
proportion (67 [30%] of 221 patients) in the control 
group had metastases, or died from prostate cancer 
compared to the escalated-dose group (65 [38%] of 
170 patients). Notably, of the 391 patients who developed 
PSA failure or progressive disease, only 220 (56%) 
reported commencing long-term salvage ADT (123 in 
the control group, 97 in the escalated-dose group). Of 
268 men who had clinical evidence of progressive 
disease, 132 (49%) developed metastases or died from 
prostate cancer (67 in the control group, 65 in the 
escalated-dose group).
According to the central, blinded review of deaths, 
91 of 236 (39%) deaths were from prostate cancer (44 in 
the control group, 47 in the escalated-dose group), 
132 (56%) were from other causes (68 in the control 
group vs 64 in the escalated-dose group), and for 13 (6%) 
patients there were insuﬃ  cient data for the reviewers to 
assign cause of death (six control vs seven escalated 
dose): for ten, the investigator deﬁ ned causality as not 
prostate cancer (which was accepted), and for the other 
three, no evidence of recurrent prostate cancer had been 
recorded. Therefore, 91 patients were deemed to have 
died from prostate cancer and 145 from other causes. 
Overall concordance between the investigators and 
clinical review was good (199 of 236, 84%; κ statistic 
0·71). 
We did a competing-risk analysis for prostate cancer 
death because 145 (61%) of 236 deaths were from causes 
other than prostate cancer, which exceeded the 
prespeciﬁ ed level of 20%. The competing-risk analysis 
showed no evidence of a diﬀ erence in death from prostate 
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Figure 4: Additional outcome measures
(A) Progression-free survival, Kaplan-Meier plot. (B) Initiation of ADT, Kaplan-Meier plot. (C) Metastases-free survival, Kaplan-Meier plot. (D) Cumulative incidence of PC deaths and non-PC deaths. 
ADT=androgen deprivation therapy. PC=prostate cancer.
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cancer. The sub-HR for the comparison of cumulative 
incidences is 1·07 (95% CI 0·71–1·61; p=0·75) in favour 
of the control group with a cause-speciﬁ c HR for prostate 
cancer deaths of 1·06 (95% CI 0·70–1·60; p=0·79) and 
for other deaths of 0·96 (0·69–1·32; p=0·78).
NCCN risk group was available for 90 of the 91 patients 
who died from prostate cancer. NCCN risk group was 
clearly related to the probability of dying from prostate 
cancer. Only one of 160 (1%) men with low-risk disease 
died from prostate cancer compared with 21 of 311 (7%) 
with intermediate-risk disease and 68 of 362 (19%) with 
high-risk disease. As a proportion of total deaths, for low-
risk disease, one (control group) of 20 (5%) were from 
prostate cancer compared with 21 (nine control vs 12 
escalated-dose) of 81 (26%) for intermediate-risk disease 
and 68 (34 control vs 34 escalated-dose) of 133 (51%) for 
high-risk disease. We identiﬁ ed no evidence of 
heterogeneity of eﬀ ect of dose escalation between these 
subgroups.
Discussion
The previously reported advantage of escalated-dose 
conformal radiotherapy treatment compared to control-
dose conformal radiotherapy in biochemical progression-
free survival after a median follow-up of about 5 years 
was maintained in the present study with more mature 
data and a median follow-up of 10 years. Using the HR, 
there was an absolute 13% (95% CI 6–19) increase in 
biochemical progression-free survival at 10 years from 
43%. This improvement in biochemical control of disease 
has not translated into an advantage for metastases-free 
survival, prostate-cancer-speciﬁ c survival, or overall 
survival. We identiﬁ ed no evidence of heterogeneity of 
treatment eﬀ ect between low, intermediate, and high-
risk groups.
We recorded a signiﬁ cant delay in the reported time to 
initiation of long-term, salvage ADT in the escalated-dose 
group; using the HR there was an absolute improvement 
of 7% (95% CI 0–12) at 10 years from 45%. This advantage 
of reducing or delaying the initiation of long-term ADT, 
which is associated with well-documented andropausal 
side-eﬀ ects,22 must be balanced against the known small 
increase in bowel side-eﬀ ects from the ﬁ ve extra 
treatments in the escalated-dose group, which we and 
others have reported.5,6,8,10,16,23
Why has the diﬀ erence in PSA control not translated 
into an advantage for metastasis-free survival and 
prostate-cancer-speciﬁ c survival? Several factors might 
be involved. First, it is likely that there were more 
indolent recurrences conﬁ ned to the prostate in the 
control group: a lower proportion of patients in the 
control group had metastases or died from prostate 
cancer than those in the escalated-dose group. Moreover, 
of patients who developed PSA failure or progressive 
disease, only 56% reported commencing long-term 
salvage ADT, and only 49% of patients who had clinical 
evidence of progressive disease developed metastases or 
died from prostate cancer. We now know that some men 
with indolent local disease do not necessarily need 
treatment, for example men with low-risk disease or 
older than 65 years do not beneﬁ t from radical 
prostatectomy,24,25 and active surveillance has become a 
standard of care for patients with a favourable outlook.26
Second, there is a long time from commencement of 
salvage ADT to death. In an international trial of 
intermittent or continuous salvage androgen suppression,22 
time from salvage ADT to death was estimated at about 
9 years, but with only about 17% of patients dying of 
prostate cancer after 7 years. In the control group of RT01, 
25% of patients had a biochemical progression-free 
survival event by 2·6 years after randomisation, but it was 
5·7 years from randomisation before 25% of patients had 
reported initiation of salvage ADT; median times for these 
outcome measures have not been reached. Moreover, our 
results clearly show that NCCN risk group was related to 
the probability of dying from prostate cancer.
The lower bound of the 95% CI for overall survival was 
0·77, and therefore our results cannot rule out some 
improvement in overall survival. More prolonged follow-
up might show a diﬀ erence in prostate-cancer mortality. 
After 14 years of follow-up, the small pilot study (N=126) 
which recruited before the start of RT01 suggested an 
overall survival advantage for the escalated-dose group 
(74 Gy) with HR 0·59, but with only 19 prostate cancer 
deaths the 95% CIs were wide (0·23–1·49).5
Our trial was designed in 1997 and launched in 1998 
before the Phoenix deﬁ nition27 for biochemical 
recurrence became established, but our chosen deﬁ nition 
of PSA failure with 2 ng/mL has much the same 
speciﬁ city and sensitivity.28 Our results are in alignment 
with reported data from other studies of dose-escalated 
external beam radiotherapy (table 3), which have shown 
absolute advantages in PSA failure-free survival of 6–19% 
for dose-escalated treatments.
Even in trials with a high proportion of patients with 
poor prognostic factors and long follow-up, none have yet 
reported prostate-cancer-speciﬁ c mortality of greater 
than 15%. When designing the RT01 trial, we anticipated 
that most patients would die of the disease. However, 
overall survival was much better than predicted and 
death from non-prostate-cancer causes was a major 
competing risk. A meta-analysis with the other 
randomised trials would provide a larger number of 
events from patients with high-risk disease to assess the 
eﬀ ect of dose-escalation on death from prostate cancer.
Our ﬁ ndings draw attention to two issues for future 
trials. First, prostate-cancer-speciﬁ c survival has 
become a diﬃ  cult outcome measure for localised 
prostate cancer trials to report in a reasonable timescale. 
Survival-based outcome measures must remain of 
paramount importance, but there are implications for 
recruiting centres, trials units, and funding bodies in 
collecting long-term data. The potential value of high-
quality, electronically linked, routinely collected 
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outcome data needs to be explored. Second, it is 
particularly important to minimise treatment-related 
side-eﬀ ects in groups of patients who are expected to 
live for a long time. We have previously reported our 
comparative side-eﬀ ect data, which we planned to 
collect only to 5 years,7,15,16 and a limitation of the present 
report is that no 10-year patient-reported outcome data 
are available.
By contrast with the dose-escalation trials, phase 3 
studies assessing the addition of neoadjuvant ADT to 
radical prostate radiotherapy have shown clear evidence 
of improved overall survival and cause-speciﬁ c survival 
in meta-analysis.29,30 Review of additional trial results11–14 
shows that survival beneﬁ ts become apparent about 
3–5 years after randomisation. One interpretation is 
that, in addition to short-course ADT having an eﬀ ect 
on local control of disease,11 6 months of ADT also has a 
direct eﬀ ect on eradication of micrometastatic disease. 
These trials have been in patients given modest doses 
of radiotherapy by present standards (equivalent to 
70 Gy or lower) but large institutional US series have 
suggested much the same beneﬁ ts of neoadjuvant ADT 
in patients given doses of 76–81 Gy.31,32
What are the relative merits of dose escalation and 
combined modality treatment with neoadjuvant ADT? 
Dose escalation leads to excellent local disease control 
using either external beam radiotherapy or 
brachytherapy33 in lower risk disease. In more advanced 
NCCN intermediate-risk or high-risk localised disease 
neoadjuvant ADT seems to improve both local control 
and reduce distant metastases. By use of a biopsy 
sample obtained 2 years after treatment as a gold 
standard method34 to detect local recurrence, a 3-month 
period of neoadjuvant ADT given with modest-dose or 
high-dose radiotherapy reduced positive biopsy ﬁ ndings 
from 46% to 10%.35 In a preplanned substudy of the 
RT01 trial, only six (6%) of 97 men in the escalated-dose 
group who agreed to have a biopsy 2 years after 
treatment had positive histology (unpublished). The 
gain of further dose escalation when given with 
neoadjuvant ADT might therefore be limited. The use 
of neoadjuvant ADT, however, must be balanced against 
the usually short-lasting increase in morbidity from 
Panel: Research in context
Systematic review
Radiotherapy dose is limited by treatment-related side-eﬀ ects. Advancing radiotherapy 
techniques using conformal radiotherapy had been shown to reduce the occurrence of 
side-eﬀ ects.3 Dose-escalation therefore became feasible with the hypothesis that higher 
radiation doses would lead to improved outcomes.5,37–39
Interpretation
As far as we are aware, this study is the largest dose-escalation trial to have reported 
long-term eﬃ  cacy results. Other dose-escalation trials5,6,8–10 in prostate cancer have shown 
an improvement in disease outcome assessed by biochemical progression-free survival. 
However, none of these trials have convincingly shown a positive eﬀ ect on overall or 
prostate-cancer-speciﬁ c survival after 10 years of follow-up. Dose escalation improves 
intermediate disease outcomes and reduces the use of salvage hormonal treatment, but at 
the cost of a modest increase in treatment-related side-eﬀ ects. Further improvements in 
radiotherapy techniques have been shown to reduce the eﬀ ect of dose-escalation on 
side-eﬀ ects4,40,41 and should be used to maintain the reported advantages of dose-escalation 
while minimising treatment sequelae. 
N Accrual 
period
Total radiation 
dose
(Gy/number of 
fractions)
NAADT NCCN risk Median 
age 
(years)
Data last 
reported
Median 
follow-
up 
(years)
PSA failure 
(N [%])
Absolute 
reduction in 
PSA failure 
in dose 
escalated 
group
Survival in 
escalated-
dose 
group
Prostate 
cancer 
deaths
(N [%])
Non-
prostate-
cancer deaths
(N [%])
Control Escalated Inter-
mediate
High
MRC RT01 843 1998–
2001
64/32 74/37 All 37% 43% 67 2012 10·0 365 (43%) 13%
(10 year)
70%
(10 year)
91 (11%) 145 (17%)
NKI9 664 1997–
2003
68/34 78/39 22% 27% 55% 69 2013 9·2 329 (50%) 6%
(10 year)
67%
(10 year)
88 (13%) 117 (18%)
PROG 95-098 393 1996–
99
70·2/39 79·2/44 No 37% 4% 67 2010 8·9 83 (21%) 16%
(10 year)
83%
(NS)
6 (1·5%) 55 (14%)
MDACC6 301 1993–
98
70/35 78/39 No 46% 34% 69 2008 8·7 61 (20%) 19%*
(8 year)
79%
(8 year)
10 (3%) 70 (23%)
ICR-RMH5 126 1995–
97
64/32 74/37 All 27% 53% 67 2013 13·7 64 (51%) 8%
(12 year)
About 
60%
(14 year)
19 (15%) 32 (25%)
GETUG 0610 306 1999–
2002
70/35 80/35 No NS 29% 67 2011 5·1 85 (28%) 8·5%
(5 year)
(NS) 10 (3·3%) 16 (5·2%)
Total 2633 ·· ·· ·· ·· ·· ·· ·· ·· ·· 987 ·· ·· 224 435
N=number of patients randomised. NAADT=short course neoadjuvant androgen deprivation therapy. NCCN=National Comprehensive Cancer Network. PSA=prostate-speciﬁ c antigen. NS=not stated. *Freedom 
from biochemical (PSA) or clinical failure.
Table 3: Data from randomised controlled trials of dose-escalated external beam radiotherapy for prostate cancer
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short-term ADT.36 Clinical trials that are in progress, 
including EORTC study 22991 (NCT00021450), will 
more completely deﬁ ne the role of combined modality 
treatment and high-dose radiotherapy.
Since we designed our trial using conformal 
radiotherapy methods, technology advances have led to 
the widespread introduction of intensity-modulated, 
image-directed, and image-guided techniques 
including the combined use of external beam 
radiotherapy with high-dose or low-dose rate brachy-
therapy, which have enabled high-dose treat ment to be 
given with a reduced prevalence of side-eﬀ ects using 
conventional or hypofractionated schedules (panel).4,40,41 
High-quality treatments are essential to maintain the 
potential advantages of dose-escalated treatment in 
improving disease control and avoiding salvage 
therapy, while maintaining low levels of treatment-
related side-eﬀ ects.
In conclusion, we have shown a clear and maintained 
advantage in biochemical (PSA) assessment of disease 
control, which has translated into a modest reduction in 
salvage ADT, but no evidence of a beneﬁ t in survival-
based outcome measures with a median follow-up of 
10 years. These eﬃ  cacy data must be weighed against the 
increase in acute and late toxicities associated with 
escalated dose.
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